Simvastatin can reduce the serum levels of PAPP-A and IL-6 in UAP patients,and it has the effects ofinhibiting the inflammation of the site of lesion and improved the stability of vulnerable plaques.

• PAPP-A、IL-6作为炎症反应的新标志物,在UAP的发生、发展中有重要的检测意义,早期应用辛伐他汀能有效降低UAP患者血清中PAPP-A、IL-6的浓度,提高冠状动脉内粥样斑块的稳定性。